Salute e Benessere
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
Working alongside more than 50 oncologic centres, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors across 40 countries in the next 18 months. By using Visium HD from 10x Genomics, Cure51 aims to uncover new insights into long-term cancer survival mechanisms and build the first proprietary multi-omics database of exceptional cancer survivors.
10x Genomics' Visium HD assay , enables researchers to perform whole transcriptome spatial gene expression analysis at single cell-scale resolution. The assay will enable Cure51's scientific and biocomputational teams and partners to generate spatial molecular profiling of tumor samples at single cell-scale resolution and gain insights into the complex interactions between the tumor cells and their microenvironment.
" said Nicolas Wolikow and Simon Istolainen, Cure51 co-Founders, who raised €15 million in Seed funding from Sofinnova, LifeX and Hitachi Ventures earlier this year.
" ," said
Ben Hindson , Co-founder and Chief Scientific Officer of 10x Genomics. " "
Clara Armand-Delille ,
clara@thirdeyemedia.press
View original content: https://www.prnewswire.co.uk/news-releases/techbio-startup-cure51-selects-10x-genomics-visium-hd-for-new-drug-discovery-initiative-302291379.html